

# Intraindividual Long-term Immune Marker Stability in Plasma Samples Collected in Median 9.4 Years Apart in 304 Adult Cancer-free Individuals

Florentin Späth<sup>1,2</sup>, Wendy Yi-Ying Wu<sup>1</sup>, Esmeralda J.M. Krop<sup>3</sup>, Ingvar A. Bergdahl<sup>4</sup>, Carl Wibom<sup>1</sup>, and Roel Vermeulen<sup>3</sup>



## ABSTRACT

**Background:** Changes in immune marker levels in the blood could be used to improve the early detection of tumor-associated inflammatory processes. To increase predictiveness and utility in cancer detection, intraindividual long-term stability in cancer-free individuals is critical for biomarker candidates as to facilitate the detection of deviation from the norm.

**Methods:** We assessed intraindividual long-term stability for 19 immune markers (IL10, IL13, TNF $\alpha$ , CXCL13, MCP-3, MIP-1 $\alpha$ , MIP-1 $\beta$ , fractalkine, VEGF, FGF-2, TGF $\alpha$ , sIL2R $\alpha$ , sIL6R, sVEGF-R2, sTNF-R1, sTNF-R2, sCD23, sCD27, and sCD30) in 304 cancer-free individuals. Repeated blood samples were collected up to 20 years apart. Intraindividual reproducibility was assessed by calculating intraclass correlation coefficients (ICC) using a linear mixed model.

**Results:** ICCs indicated fair to good reproducibility (ICCs  $\geq$  0.40 and  $<$  0.75) for 17 of 19 investigated immune markers, including

IL10, IL13, TNF $\alpha$ , CXCL13, MCP-3, MIP-1 $\alpha$ , MIP-1 $\beta$ , fractalkine, VEGF, FGF-2, TGF $\alpha$ , sIL2R $\alpha$ , sIL6R, sTNF-R1, sTNF-R2, sCD23, and sCD30. Reproducibility was strong (ICC  $\geq$  0.75) for sCD23, while reproducibility was poor (ICC  $<$  0.40) for sVEGF-R2. Using a more stringent criterion for reproducibility (ICC  $\geq$  0.55), we observed either acceptable or better reproducibility for IL10, IL13, CXCL13, MCP-3, MIP-1 $\alpha$ , MIP-1 $\beta$ , VEGF, FGF-2, sTNF-R1, sCD23, sCD27, and sCD30.

**Conclusions:** IL10, IL13, CXCL13, MCP-3, MIP-1 $\alpha$ , MIP-1 $\beta$ , VEGF, FGF-2, sTNF-R1, sCD23, sCD27, and sCD30 displayed ICCs consistent with intraindividual long-term stability in cancer-free individuals.

**Impact:** Our data support using these markers in prospective longitudinal studies seeking early cancer detection biomarkers.

## Introduction

Worldwide cancer mortality is increasing and in many countries cancer has become the leading cause of death (1). These observations support early cancer detection programs to improve cancer prognosis (2). As immune alteration and inflammation promote tumor development and progression (3), changes in immune or inflammatory markers in the blood could help to improve early detection of cancer (4, 5). In cancer-free individuals, early cancer detection biomarkers should be stable over time (6, 7).

Several previous studies have investigated intraindividual immune marker stability (8–27). These studies were characterized by: small study size ( $N <$  40; refs. 8–15); limited generalizability to more diverse populations (e.g., the participants were either female or male or healthy and young; refs. 8–13, 16–24); and/or blood samples collected within a short period ( $<$ 2 years; refs. 10–14, 22, 23, 25–27; i.e., the samples do

not provide accurate information on intraindividual long-term marker stability). However, for the evaluation of early cancer detection biomarker candidates, it is important to provide information about the degree of the long-term intraindividual marker stability in cancer-free individuals.

In this study, we determined the intraindividual long-term immune marker stability by assessing the intraclass correlation coefficients (ICC) of 19 immune markers in repeated blood samples collected 9.4 years (median) apart in a cohort of 304 middle-aged cancer-free women and men. The analyzed immune markers were: cytokines (IL10, IL13, and TNF $\alpha$ ); chemokines [C-X-C motif ligand 13 (CXCL13), monocyte chemoattractant protein (MCP)-3, macrophage inflammatory protein (MIP)-1 $\alpha$ , MIP-1 $\beta$ , and fractalkine]; proangiogenic or mitogenic growth factors (VEGF, FGF-2, and TGF $\alpha$ ); and soluble (s) forms of cell surface receptors (sIL2R $\alpha$ , sIL6R, sVEGF-R2, sTNF-R1, sTNF-R2, sCD23, sCD27, and sCD30).

## Materials and Methods

### Study population

Participants were recruited from three nested case–control studies. These earlier studies investigated disease risk in relation to changes in blood immune marker levels or metabolomic patterns (28–30). Participants of the present study ( $N = 304$ ) were cancer-free individuals who had two (or more) blood samples available within the Northern Sweden Health and Disease Study (NSHDS; ref. 31). NSHDS consists of three subcohorts: the Västerbotten Intervention Program (VIP), the Mammary Screening Project (MA), and the Northern Sweden Monica Project. For this study, one first and one repeated blood sample were selected for each participant using both VIP and MA. VIP is a population-based cohort of individuals 40, 50, and 60 years of age

<sup>1</sup>Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden.

<sup>2</sup>Department of Radiation Sciences, Oncology, Cancer Center, Department of Hematology, Umeå University, Umeå, Sweden. <sup>3</sup>Division of Environmental Epidemiology, Institute for Risk Assessment Sciences, Utrecht University, Utrecht, the Netherlands. <sup>4</sup>Department of Biobank Research, Umeå University, Umeå, Sweden.

**Note:** Supplementary data for this article are available at Cancer Epidemiology, Biomarkers & Prevention Online (<http://cebp.aacrjournals.org/>).

**Corresponding Author:** Florentin Späth, Department of Radiation Sciences, Oncology, Department of Hematology, Umeå University, Umeå 90187, Sweden. Phone: 469-0785-0000; Fax: 469-077-4646; E-mail: florentin.spaeth@umu.se

Cancer Epidemiol Biomarkers Prev 2021;30:2052–8

doi: 10.1158/1055-9965.EPI-21-0509

©2021 American Association for Cancer Research

who have donated blood samples within health surveys since 1985. MA is a cohort of females attending mammary screening with repeated blood samples available between 1995 and 2006. Linkage of NSHDS to the Swedish Cancer Registry (median follow-up time after the last sample: 4 years) facilitated selection of cancer-free individuals (32). All blood samples were frozen within one hour of collection and stored at  $-80^{\circ}\text{C}$  at Umeå University Hospital (Umeå, Sweden). This study was approved by the Ethical Review Board at Umeå University (Umeå, Sweden) and was performed in compliance with the declaration of Helsinki.

**Immune marker measurement**

Repeated immune marker levels were assessed in all participants in one laboratory effort using multiplex bead-based immunoassays (Luminex): the Milliplex HCYTOMAG-60K kit (Millipore) was used to analyze IL10, IL13, TNF $\alpha$ , MCP-3, MIP-1 $\alpha$ , MIP-1 $\beta$ , fractalkine, VEGF, FGF-2, and TGF $\alpha$ ; the Milliplex HSCRMAG-32K kit (Millipore) was used to analyze sIL2R $\alpha$ , sIL6R, sVEGF-R2, and sTNF-R2; and the LXSAM kit (R&D Systems) was used to analyze CXCL13 and sTNF-R1. ELISAs (eBioscience) were used to analyze blood levels of sCD23, sCD27, and sCD30. In most study participants ( $N = 286$ ), the first and repeated sample were placed in random order on the same analysis plate to minimize plate-mediated effects. Laboratory personnel were blinded concerning the chronological order of the samples. The same experienced lab technician performed all analyses according to the manufacturers' protocols. All markers were measured in duplicate with exception of the quantification of sCD30 (due to limited sample volume). For statistical analyses, duplicate immune marker measures were averaged.

**Statistical analyses**

Immune marker concentration data were visually inspected and evaluated for normality. Because of right-skewing, all immune markers were natural log transformed to improve normality. To reduce the influence of extreme values, immune marker concentrations were winsorized to the 1st and 99th percentile (28, 29). Immune marker concentrations below the limit of quantification (LoQ; 2.4% of all performed measurements) were treated as missing values.

To assess the temporal reproducibility of repeated immune marker measures, we calculated intraclass correlation coefficients (ICC) and 95% confidence intervals (CI) for each immune marker [i.e., between-individual variability in relation to the total variability (between-individual variability + within-individual variability)]. ICCs and 95% CIs were estimated by fitting a linear mixed model using the lme4 package (33) in the R software. The linear mixed model included analysis plate and subject (nested within analysis plate) as random intercepts to account for repeated immune marker measures. The model was also adjusted for sex and age (continuous in years at the time of blood draw) by including both variables as fixed effects. The 95% CIs were calculated for all estimated ICCs using the bootstrapping approach. Rosner interpretation of ICCs was applied to evaluate intraindividual reproducibility of repeated immune marker measurements: ICCs < 0.4 indicate poor reproducibility; ICCs between 0.40 and 0.75 indicate fair to good reproducibility; and ICCs  $\geq 0.75$  indicate strong reproducibility (34). In addition, we used a more stringent criterion for evaluating immune marker reproducibility with ICCs  $\geq 0.55$  indicating acceptable reproducibility (19).

Intraindividual marker stability was evaluated in subpopulations. To investigate the influence of the time interval between blood sample collections on the marker stability, we stratified individuals by the time

between the first and repeated blood draw (>3–10 years and >10–20 years). Next, we stratified the dataset by sex to investigate intraindividual marker stability in female ( $N = 212$ ) and male ( $N = 92$ ) study participants separately. In addition, we investigated differences in intraindividual marker stability with regard to body mass index (BMI) and smoking status.

Sensitivity analyses were performed to assess the robustness of the results. To exclude plate-mediated effects on estimated ICCs, we restricted analyses to a dataset with all participants having their first and repeated blood sample placed on the same analysis plate ( $N = 286$ ). Other processes such as the participant's fasting status or diurnal variation of immune marker concentrations could influence the estimated intraindividual marker stability. To minimize the influence of such processes, we restricted analyses to a dataset with all participants donating their first and repeated blood sample to VIP ( $N = 135$ ) because within VIP the majority of blood samples are drawn in the morning after overnight fasting.

All statistical analyses were performed using the R environment for biostatistical computing (The R Foundation for Biostatistical Computing).

**Results**

Intraindividual long-term stability of 19 immune markers including cytokines, chemokines, growth factors, and soluble cell surface receptors was investigated in repeated blood samples. Blood samples were collected from 304 individuals in median 9 years apart between November 1986 and May 2010. Participants of this study ( $N = 304$ ) were selected from the general population with a median cancer-free follow-up time of 4 years (Table 1). At the first and repeated blood sample draw, the median age was 50 and 60 years, respectively. About one-third ( $N = 224$ ) of all samples ( $N = 608$ ) were retrieved from MA (mammography cohort), explaining the higher proportion of females (70%) in this study (Table 1).

The majority (97.6%) of all measurements ( $N = 12,768$ ) were above the LoQ (Table 2). Intraassay coefficients of variation (CV) of duplicate immune marker measures ranged between 7.6% for sCD23 and 19.1% for TGF $\alpha$ . Inter-assay CVs based on one quality control sample were relatively high for all markers and ranged between 15.0% for sCD30 and 47.4% for sCD27 (Table 2). Median immune marker

**Table 1.** Descriptive statistics of included blood samples and cancer-free participants.

Characteristic	N	Median	Range
Age (years)			
First blood sample	304	50.1	30.0–68.8
Repeated blood sample	304	60.0	39.7–73.7
Cancer-free years from repeated blood sample	304	4.2	0.0–17.0
Year of blood sample collection			
First blood sample	304	1994	1986–2002
Repeated blood sample	304	2002	1995–2010
Years between blood sample collection	304	9.4	0.1–20
Gender			
Female	212		
Male	92		
Body mass index (kg/m <sup>2</sup> )			
First blood sample	290	25.1	17.1–40.3
Repeated blood sample	269	25.6	15.8–44.6

Downloaded from <http://aacrjournals.org/cebp/article-pdf/30/11/2052/3100369/2052.pdf> by guest on 14 June 2024

**Table 2.** Proportion of measurements above the LoQ, and intraassay and interassay CVs.

Marker	LoQ (%)	Intraassay CV (%)	Interassay CV (%)
IL10 <sup>a</sup>	95.9	15.4	42.9
IL13 <sup>a</sup>	93.6	16.1	36.9
TNF $\alpha$ <sup>a</sup>	96.1	11.9	36.4
CXCL13 <sup>a</sup>	99.5	10.7	41.0
MCP-3 <sup>a</sup>	96.7	14.4	36.4
MIP-1 $\alpha$ <sup>a</sup>	97.9	18.7	44.4
MIP-1 $\beta$ <sup>a</sup>	95.4	13.8	27.9
Fractalkine <sup>a</sup>	99.8	14.9	24.9
VEGF <sup>a</sup>	99.2	17.9	19.3
FGF-2 <sup>a</sup>	99.2	15.4	24.1
TGF $\alpha$ <sup>a</sup>	84.4	19.1	48.2
sIL2R $\alpha$ <sup>a</sup>	98.4	11.8	29.4
sIL6R <sup>a</sup>	100.0	8.9	18.6
sTNF-R1 <sup>a</sup>	99.3	8.7	15.3
sTNF-R2 <sup>a</sup>	100.0	9.6	17.2
sVEGF-R2 <sup>a</sup>	100.0	9.3	33.7
sCD23 <sup>b</sup>	100.0	7.6	18.7
sCD27 <sup>b</sup>	99.5	16.6	47.4
sCD30 <sup>b</sup>	96.9	<sup>c</sup>	15.0

<sup>a</sup>Assessed by Luminex multiplex kit.<sup>b</sup>Assessed by singleplex ELISA.<sup>c</sup>sCD30 not assessed in duplicate.

concentrations and median percentage changes of immune markers are presented in **Table 3**.

In all immune markers, we evaluated reproducibility (or intraindividual marker stability) by calculating ICCs between measures of

the first and repeated blood draw. On the basis of calculated ICCs, we observed fair to good reproducibility (ICC between 0.40 and 0.75) for 17 of 19 investigated immune markers including IL10, IL13, TNF $\alpha$ , CXCL13, MCP-3, MIP-1 $\alpha$ , MIP-1 $\beta$ , fractalkine, VEGF, FGF-2, TGF $\alpha$ , sIL2R $\alpha$ , sIL6R, sTNF-R1, sTNF-R2, sCD27, and sCD30 (**Fig. 1**). Reproducibility was strong (ICC  $\geq$  0.75) for sCD23, while reproducibility was poor (ICC < 0.40) for sVEGF-R2 (**Fig. 1**). Using a more stringent criteria for reproducibility (ICC  $\geq$  0.55), we observed acceptable reproducibility for IL10, IL13, CXCL13, MCP-3, MIP-1 $\alpha$ , MIP-1 $\beta$ , VEGF, FGF-2, sTNF-R1, sCD23, sCD27, and sCD30 (**Fig. 1**).


We evaluated the influence of the time interval between the first and repeated blood draw on the estimated marker stability. Participants were stratified according to two different intervals between the first and repeated blood draw (>3–10 years and >10–20 years). In these analyses, ICCs were of approximately similar size for IL10, IL13, CXCL13, MCP-3, sIL6R, sTNF-R2, sCD23, and sCD30 in both time intervals (**Table 4**). ICCs were somewhat lower in individuals within the longest time interval (>10–20 years) between the first and repeated blood draw for most of the investigated markers including TNF $\alpha$ , MIP-1 $\alpha$ , MIP-1 $\beta$ , fractalkine, VEGF, FGF-2, TGF $\alpha$ , sIL2R $\alpha$ , sTNF-R1, and sCD27 (**Table 4**).

Analyses stratified by sex displayed similar ICCs in most immune markers. ICCs were lower in men for MIP-1 $\alpha$ , MIP-1 $\beta$ , sIL2R $\alpha$ , and sCD30 as compared with ICCs derived from all study participants. Evaluating this result, it is important to consider that the time between blood draw was in median (SD) 10.0 (1.8) years and 6.1 (4.1) years in men and women, respectively (**Table 4**). This difference is explained by the generally shorter interval between blood draw in MA (4 years) as compared with VIP (10 years). However, similar results were obtained when repeating sex-stratified analyses restricted to participants with >8 years between blood draw,

**Table 3.** Median and median percent change of immune marker concentrations assessed in repeated blood samples collected in median 9.4 years apart.

Marker	First sample Median (5th–95th percentile)	Repeated sample Median (5th–95th percentile)	Median % change <sup>a</sup> (5th–95th percentile)
IL10 <sup>b</sup>	12.1 (1.3–41.4)	11.3 (1.4–46.3)	–3% (–76% to 336%)
IL13 <sup>b</sup>	19.7 (3.4–73.4)	19.5 (3.9–68.4)	0% (–50% to 120%)
TNF $\alpha$ <sup>b</sup>	12.7 (5.2–27.7)	11.9 (4.8–31.1)	–2% (–56% to 106%)
CXCL13 <sup>b</sup>	66.3 (32.5–144.8)	66.4 (31.0–150.4)	1% (–41% to 77%)
MCP-3 <sup>b</sup>	56.7 (18.4–137.5)	55.6 (23.1–155.8)	0% (–50% to 120%)
MIP-1 $\alpha$ <sup>b</sup>	9.0 (2.7–22.7)	8.3 (2.5–22.4)	–7% (–64% to 108%)
MIP-1 $\beta$ <sup>b</sup>	39.5 (18.5–88.5)	38.2 (16.8–92.4)	–3% (–52% to 71%)
Fractalkine <sup>b</sup>	328 (155–653)	296 (141–665)	–6% (–62% to 80%)
VEGF <sup>b</sup>	362 (132–1,100)	346 (119–1,173)	–1% (–60% to 131%)
FGF-2 <sup>b</sup>	245 (100–554)	235 (98–512)	–7% (–55% to 94%)
TGF $\alpha$ <sup>b</sup>	3.9 (0.6–11.8)	3.9 (0.6–15.1)	–3% (–81% to 392%)
sIL2R $\alpha$ <sup>b</sup>	400 (192–807)	426 (188–1,021)	6% (–44% to 152%)
sIL6R <sup>b</sup>	15,261 (8,679–25,079)	15,308 (9,301–26,102)	0% (–39% to 69%)
sTNF-R1 <sup>b</sup>	3,393 (2,342–5,056)	3,688 (2,450–6,009)	7% (–21% to 66%)
sTNF-R2 <sup>b</sup>	5,055 (3,250–7,815)	5,316 (3,397–9,493)	4% (–29% to 75%)
sVEGF-R2 <sup>b</sup>	12,474 (7,719–19,431)	12,331 (7,823–21,107)	0% (–38% to 74%)
sCD23 <sup>b</sup>	2,194 (1,031–4,219)	2,314 (1,048–4,970)	3% (–25% to 66%)
sCD27 <sup>c</sup>	18.2 (7.2–35.8)	18.9 (7.5–42.8)	2% (–33% to 80%)
sCD30 <sup>d</sup>	2.5 (1.5–5.2)	2.5 (1.4–6.0)	0% (–46% to 86%)

<sup>a</sup>Calculated by [(Marker level<sub>Repeated sample</sub> – Marker level<sub>First sample</sub>)/Marker level<sub>First sample</sub>]  $\times$  100.<sup>b</sup>Marker concentration in pg/mL.<sup>c</sup>Marker concentration in U/mL.<sup>d</sup>Marker concentration in ng/mL.



**Figure 1.** ICCs and 95% CIs of all investigated immune markers. Immune markers investigated were cytokines (IL10, IL13, and TNF $\alpha$ ), chemokines (CXCL13, MCP-3, MIP-1 $\alpha$ , MIP-1 $\beta$ , and fractalkine), growth factors (VEGF, FGF-2, and TGF $\alpha$ ), and soluble cell surface receptors (sIL2R $\alpha$ , sIL6R, sVEGF-R2, sTNF-R1, sTNF-R2, sCD23, sCD27, and sCD30). ICCs were estimated by linear mixed effects modeling adjusted for age, sex, and analysis plate. Fair immune marker reproducibility (ICC  $\geq$  0.40) is indicated by the red solid line. A more stringent criterion for acceptable marker reproducibility (ICC  $\geq$  0.55) is indicated by the black dashed line.

supporting true sex-specific differences of the long-term marker stability in MIP-1 $\alpha$ , MIP-1 $\beta$ , sIL2R $\alpha$ , and sCD30. Analyses stratified by BMI into healthy weight (BMI, 18.5–24.9 kg/m<sup>2</sup>) and overweight or obese (BMI  $\geq$  25.0 kg/m<sup>2</sup>) individuals displayed ICCs of similar size in most markers (Supplementary Table S1). The ICC for sCD27 was lower in overweight or obese individuals (ICC = 0.41) compared with healthy weight participants (ICC = 0.78). Analyses stratified by smoking status showed that current or former

smokers had somewhat lower ICCs for TGF $\alpha$ , sVEGF-R2, and sCD27 than never smokers (Supplementary Table S1).

Sensitivity analyses, restricted to a data set with all participants having their first and repeated blood sample on the same analysis plate ( $N = 286$ ), did not provide indication of a significant plate-mediated effect on estimated intraindividual marker stability. In addition, we restricted analyses to a dataset with all participants donating their first and repeated blood sample to VIP ( $N = 135$ ) with the majority of the

**Table 4.** Long-term immune marker reproducibility as evaluated by ICCs and 95% CIs in all participants and stratified by the time between blood draws and sex.

Marker	All participants $N = 304$ ICC <sup>a</sup> (95% CI)	>3 to 10 years <sup>b</sup> $N = 168$ ICC <sup>a</sup> (95% CI)	>10 to 20 years <sup>c</sup> $N = 82$ ICC <sup>a</sup> (95% CI)	Females <sup>d</sup> $N = 212$ ICC <sup>e</sup> (95% CI)	Males <sup>f</sup> $N = 92$ ICC <sup>e</sup> (95% CI)
IL10	0.56 (0.47–0.65)	0.61 (0.50–0.71)	0.52 (0.31–0.67)	0.54 (0.43–0.63)	0.59 (0.43–0.72)
IL13	0.58 (0.50–0.66)	0.53 (0.41–0.64)	0.68 (0.52–0.79)	0.56 (0.45–0.65)	0.62 (0.46–0.75)
TNF $\alpha$	0.51 (0.41–0.59)	0.57 (0.44–0.68)	0.36 (0.13–0.56)	0.53 (0.42–0.63)	0.45 (0.27–0.60)
CXCL13	0.62 (0.54–0.69)	0.57 (0.46–0.67)	0.66 (0.50–0.77)	0.62 (0.53–0.69)	0.61 (0.45–0.73)
MCP-3	0.68 (0.61–0.74)	0.70 (0.62–0.78)	0.64 (0.47–0.76)	0.69 (0.60–0.76)	0.66 (0.53–0.77)
MIP-1 $\alpha$	0.57 (0.49–0.65)	0.63 (0.53–0.72)	0.44 (0.24–0.62)	0.66 (0.57–0.74)	0.44 (0.24–0.61)
MIP-1 $\beta$	0.66 (0.60–0.72)	0.69 (0.60–0.77)	0.53 (0.32–0.69)	0.73 (0.66–0.79)	0.53 (0.38–0.67)
Fractalkine	0.47 (0.37–0.56)	0.52 (0.40–0.63)	0.37 (0.14–0.55)	0.48 (0.35–0.58)	0.44 (0.25–0.59)
VEGF	0.55 (0.46–0.63)	0.65 (0.54–0.73)	0.45 (0.25–0.62)	0.54 (0.43–0.63)	0.56 (0.39–0.69)
FGF-2	0.57 (0.49–0.64)	0.60 (0.49–0.69)	0.46 (0.25–0.62)	0.59 (0.49–0.69)	0.51 (0.34–0.65)
TGF $\alpha$	0.48 (0.37–0.58)	0.57 (0.44–0.68)	0.35 (0.10–0.59)	0.53 (0.41–0.64)	0.40 (0.19–0.59)
sIL2R $\alpha$	0.42 (0.32–0.52)	0.44 (0.30–0.57)	0.23 (0.01–0.46)	0.47 (0.36–0.58)	0.29 (0.07–0.47)
sIL6R	0.52 (0.43–0.60)	0.48 (0.34–0.61)	0.53 (0.35–0.67)	0.55 (0.44–0.64)	0.44 (0.24–0.59)
sTNF-R1	0.61 (0.54–0.67)	0.60 (0.47–0.70)	0.53 (0.33–0.68)	0.63 (0.54–0.71)	0.56 (0.41–0.70)
sTNF-R2	0.50 (0.40–0.58)	0.47 (0.33–0.59)	0.48 (0.30–0.65)	0.50 (0.38–0.59)	0.48 (0.31–0.63)
sVEGF-R2	0.33 (0.22–0.43)	0.24 (0.08–0.39)	0.42 (0.20–0.61)	0.31 (0.17–0.44)	0.38 (0.18–0.55)
sCD23	0.75 (0.70–0.80)	0.70 (0.61–0.78)	0.75 (0.62–0.84)	0.76 (0.70–0.82)	0.72 (0.61–0.81)
sCD27	0.68 (0.61–0.74)	0.79 (0.72–0.84)	0.44 (0.21–0.63)	0.74 (0.67–0.80)	0.63 (0.48–0.75)
sCD30	0.56 (0.46–0.64)	0.59 (0.48–0.69)	0.54 (0.38–0.68)	0.63 (0.54–0.70)	0.35 (0.12–0.53)

<sup>a</sup>ICCs were estimated by linear mixed effects modeling adjusted for age at blood draw, sex, and analysis plate.

<sup>b</sup>Analyses including individuals with >3 to 10 years between first and repeated blood draws ( $N_{\text{Females}} = 114$ ;  $N_{\text{Males}} = 54$ ).

<sup>c</sup>Analyses including individuals with >10 to 20 years between first and repeated blood draws ( $N_{\text{Females}} = 44$ ;  $N_{\text{Males}} = 38$ ).

<sup>d</sup>Analyses including female participants (median time  $\pm$  SD between first and repeated blood draws was 6.1  $\pm$  4.1 years).

<sup>e</sup>ICCs were estimated by linear mixed effects modeling adjusted for age at blood draw and analysis plate.

<sup>f</sup>Analyses including male participants (median time  $\pm$  SD between first and repeated blood draws was 10.0  $\pm$  1.8 years).

samples collected in the morning after overnight fasting. Results from these analyses remained similar for most markers with exception of MIP-1 $\alpha$  and sCD30 which slightly decreased in ICCs from 0.57 to 0.48 and from 0.56 to 0.45, respectively.

## Discussion

Improved cancer control could be achieved by using blood-based screening strategies allowing the detection of tumor-related molecules (35). Because tumor development and progression are affected by inflammatory processes (36), the identification of immune marker changes has a promising role for early cancer detection. Identification of tumor-specific changes in immune marker levels requires high intraindividual long-term stability of potential biomarker candidates in cancer-free individuals (6, 7). Using repeated blood samples from NSHDS, we were able to collect data on intraindividual long-term immune marker stability in 304 cancer-free individuals.

Our results suggest fair reproducibility (ICC  $\geq$  0.40) in repeated blood samples collected up to 20 years apart for 18 of 19 investigated immune markers. Using a more stringent reproducibility criterion (ICC  $\geq$  0.55; ref. 19), IL10, IL13, CXCL13, MCP-3, MIP-1 $\alpha$ , MIP-1 $\beta$ , VEGF, FGF-2, sTNF-R1, sCD23, sCD27, and sCD30 showed acceptable reproducibility (Fig. 1). Reproducibility of this magnitude (ICC  $\geq$  0.55) is consistent with high intraindividual marker stability over the long term (20). High long-term marker stability in cancer-free individuals suggests a potential use for the identification of tumor-associated inflammatory processes by IL10, IL13, CXCL13, MCP-3, MIP-1 $\alpha$ , MIP-1 $\beta$ , VEGF, FGF-2, sTNF-R1, sCD23, sCD27, and sCD30. Our results also suggest that the effect of fasting status on ICCs is small for most of the studied markers.

Interestingly, several markers displaying intraindividual long-term stability in this study, have been suggested to be of potential early diagnostic value in different cancers such as gastric cancer (IL10; ref. 37), ovarian cancer (IL13; ref. 38), lung cancer (IL10, CXCL13, and VEGF; refs. 39–41), multiple myeloma (MCP-3, MIP-1 $\alpha$ , VEGF, and FGF-2; ref. 29), nasopharyngeal carcinoma (MIP-1 $\alpha$  and MIP-1 $\beta$ ; ref. 42), colon cancer (MIP-1 $\alpha$ ; ref. 43), and B-cell lymphoma (CXCL13, sCD23, sCD27, and sCD30; refs. 28, 44).

In the case of lower reproducibility (ICCs between 0.40 and 0.55), attenuated associations between marker levels and cancer are expected (20, 45). However, strong biomarker candidates suitable for early cancer detection are assumed to display blood level changes of large effect size in individuals later diagnosed with cancer (46, 47). Therefore, immune markers with ICCs between 0.40 and 0.55 such as TNF $\alpha$ , fractalkine, TGF $\alpha$ , sIL2R $\alpha$ , sIL6R, and sTNF-R2 could also be of value for the early identification of tumor-associated inflammatory processes. Fair reproducibility as estimated for fractalkine, TGF $\alpha$ , and sIL2R $\alpha$  should be interpreted carefully because the lower CI of estimated ICCs was below 0.40 for these markers (Fig. 1).

Intraindividual marker variability was evaluated in several studies using repeated blood samples collected  $\leq$  3 years apart. Compared with our repeated blood samples collection of up to 20 years apart, these studies observed higher ICCs for IL10 (9, 21), IL13 (9), TNF $\alpha$  (9, 19, 21, 22), MIP-1 $\alpha$  (17), fractalkine (16, 17), sIL2R $\alpha$  (9, 21), sTNF-R1 (25), sTNF-R2 (9, 19, 21, 22, 25), and sVEGF-R2 (16). The discrepancies suggest, that high reproducibility in the short-term does not necessarily imply high reproducibility in the long term.

ICCs observed in our cohort were more comparable with long-term ICCs reported by two previous studies investigating immune marker reproducibility in samples collected  $\geq$  5 years apart (15, 20). As

compared with our study, these studies' ICCs for IL10 (15, 20), CXCL13 (20), and sCD27 (20) were similar. In contrast, ICCs for IL13 (15), sTNF-R2, and sIL2R $\alpha$  (20) indicated higher reproducibility for these markers in previous studies than observed by us. However, it is important to note that participants in McKay and colleagues study (20) were all young to middle-aged men ( $N = 250$ ) who donated repeated blood samples up to more than 15 years apart. Hofmann and colleagues study (15) included a relatively small number ( $N = 28$ ) of participants who donated repeated blood samples up to 5 years apart. Different time intervals for blood draws and differences in the studied populations might have contributed to the differences in observed ICCs.

To the best of our knowledge, this study is among the largest studies reporting on intraindividual long-term immune marker stability in cancer-free individuals. To evaluate long-term marker stability, blood samples were collected up to 20 years apart. During this period, sample collection and processing did not change within NSHDS. Duplicate analyte measurement (except of sCD30) is another strength of this study. Our study also has some limitations. Because of limited sample size, results of subanalyses should be interpreted with caution. Participants in the study had one repeated blood sample available collected in median 9 years apart. Additional information on the short-term marker variability based on samples collected within a shorter interval would have improved this study. As immuno-oncological mechanisms are complex, a broader evaluation of immune marker levels, including systems immunology analyses allowing to study variations of immune cell components, would have been of high interest (48). Blood immune marker changes likely are influenced by any acute or chronic disease processes that were present at the time of blood draw. The lack of this information is a drawback of the study. However, it might be assumed that general health survey participants (VIP) would have rescheduled appointments in case of acute infections. In addition, it is important to recognize that target populations for early cancer detection programs likely also include individuals with inflammatory processes related to other diseases than cancer.

In conclusion, we observed high intraindividual stability in marker levels in 304 cancer-free individuals over a period of up to 20 years for IL10, IL13, CXCL13, MCP-3, MIP-1 $\alpha$ , MIP-1 $\beta$ , VEGF, FGF-2, sTNF-R1, sCD23, sCD27, and sCD30. Given expected cancer latency times (49), changes in blood levels of these markers could help identify early tumor-associated inflammatory processes. On the basis of high-throughput proteomics (50), future studies should assess both intraindividual short- and long-term marker stability in a large cohort of cancer-free individuals. This strategy could provide a broader perspective of the biological variability and the potential utility for early cancer detection for a wide range of markers.

## Authors' Disclosures

F. Späth reports grants from Cancer Research Foundation in Northern Sweden during the conduct of the study. I.A. Bergdahl reports grants from Swedish Research Council during the conduct of the study. No disclosures were reported by the other authors.

## Authors' Contributions

F. Späth: Conceptualization, data curation, formal analysis, supervision, funding acquisition, investigation, visualization, methodology, writing—original draft, writing—review and editing. W.Y.-Y. Wu: Formal analysis, investigation, methodology, writing—review and editing. E.J.M. Krop: Data curation, writing—review and editing, laboratory analyses. I.A. Bergdahl: Supervision, methodology, writing—review and editing. C. Wibom: Conceptualization, formal analysis, supervision, methodology, writing—review and editing. R. Vermeulen: Supervision, methodology, writing—review and editing.

## Acknowledgments

We wish to thank the Biobank Research Unit at Umeå University, VIP, MA, and the County Council of Västerbotten for providing data and samples and acknowledge the contribution from Biobank Sweden, supported by the Swedish Research Council (VR 2017-00650). The study was funded by the Cancer Research Foundation in Northern Sweden (F. Späth) and the regional agreement between Umeå University and Västerbotten County Council (ALF; F. Späth).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received April 19, 2021; revised June 22, 2021; accepted August 9, 2021; published first August 23, 2021.

## References

- Dagenais GR, Leong DP, Rangarajan S, Lanas F, Lopez-Jaramillo P, Gupta R, et al. Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study. *Lancet* 2019;395:785–94.
- Hawkes N. Cancer survival data emphasise importance of early diagnosis. *BMJ* 2019;364:l408.
- Shalapour S, Karin M. Immunity, inflammation, and cancer: an eternal fight between good and evil. *J Clin Invest* 2015;125:3347–55.
- Brenner DR, Scherer D, Muir K, Schildkraut J, Boffetta P, Spitz MR, et al. A review of the application of inflammatory biomarkers in epidemiologic cancer research. *Cancer Epidemiol Biomarkers Prev* 2014;23:1729–51.
- Carrick DM, Chaturvedi AK, Shiels MS, Divi RL, Filipiński KK, Hebert EF, et al. Using immune marker panels to evaluate the role of inflammation in cancer: summary of an NCI-sponsored workshop. *Cancer Epidemiol Biomarkers Prev* 2015;24:1427–33.
- McIntosh MW, Urban N, Karlan B. Generating longitudinal screening algorithms using novel biomarkers for disease. *Cancer Epidemiol Biomarkers Prev* 2002;11:159–66.
- Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, et al. Phases of biomarker development for early detection of cancer. *J Natl Cancer Inst* 2001;93:1054–61.
- Kaplan RC, Ho GYF, Xue X, Rajpathak S, Cushman M, Rohan TE, et al. Within-individual stability of obesity-related biomarkers among women. *Cancer Epidemiol Biomarkers Prev* 2007;16:1291–3.
- Clendenen TV, Arslan AA, Lokshin AE, Idahl A, Hallmans G, Koenig KL, et al. Temporal reliability of cytokines and growth factors in EDTA plasma. *BMC Res Notes* 2010;3:302.
- Mueller SC, März R, Schmolz M, Drewelow B. Intraindividual long term stability and response corridors of cytokines in healthy volunteers detected by a standardized whole-blood culture system for bed-side application. *BMC Med Res Methodol* 2012;12:112.
- Aziz N, Detels R, Quint JJ, Gjertson D, Ryner T, Butch AW. Biological variation of immunological blood biomarkers in healthy individuals and quality goals for biomarker tests. *BMC Immunol* 2019;20:33.
- Hosnijeh FS, Krop EJM, Portengen L, Rabkin CS, Linseisen J, Vineis P, et al. Stability and reproducibility of simultaneously detected plasma and serum cytokine levels in asymptomatic subjects. *Biomarkers* 2010;15:140–8.
- Wu D, Dinh TL, Bausk BP, Walt DR. Long-term measurements of human inflammatory cytokines reveal complex baseline variations between individuals. *Am J Pathol* 2017;187:2620–6.
- Wong H-L, Pfeiffer RM, Fears TR, Vermeulen R, Ji S, Rabkin CS. Reproducibility and correlations of multiplex cytokine levels in asymptomatic persons. *Cancer Epidemiol Biomarkers Prev* 2008;17:3450–6.
- Hofmann JN, Yu K, Bagni RK, Lan Q, Rothman N, Purdue MP. Intra-individual variability over time in serum cytokine levels among participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. *Cytokine* 2011;56:145–8.
- Agalliu I, Xue X, Cushman M, Cornell E, Hsing AW, Kaplan RC, et al. Detectability and reproducibility of plasma levels of chemokines and soluble receptors. *Results Immunol* 2013;3:79–84.
- Linkov F, Gu Y, Arslan AA, Liu M, Shore RE, Velikokhatnaya L, et al. Reliability of tumor markers, chemokines, and metastasis-related molecules in serum. *Eur Cytokine Netw* 2009;20:21–6.
- Enroth S, Hallmans G, Grankvist K, Gyllenstein U. Effects of long-term storage time and original sampling month on biobank plasma protein concentrations. *EBioMedicine* 2016;12:309–14.
- Gu Y, Zeleniuch-Jacquotte A, Linkov F, Koenig KL, Liu M, Velikokhatnaya L, et al. Reproducibility of serum cytokines and growth factors. *Cytokine* 2009;45:44–9.
- McKay HS, Margolick JB, Martínez-Maza O, Lopez J, Phair J, Rappocciolo G, et al. Multiplex assay reliability and long-term intra-individual variation of serologic inflammatory biomarkers. *Cytokine* 2017;90:185–92.
- Epstein MM, Breen EC, Magpantay L, Detels R, Lepone L, Penugonda S, et al. Temporal stability of serum concentrations of cytokines and soluble receptors measured across two years in low-risk HIV-seronegative men. *Cancer Epidemiol Biomarkers Prev* 2013;22:2009–15.
- Navarro SL, Brasky TM, Schwarz Y, Song X, Wang CY, Kristal AR, et al. Reliability of serum biomarkers of inflammation from repeated measures in healthy individuals. *Cancer Epidemiol Biomarkers Prev* 2012;21:1167–70.
- Biancotto A, Wank A, Perl S, Cook W, Olnes MJ, Dagur PK, et al. Baseline levels and temporal stability of 27 multiplexed serum cytokine concentrations in healthy subjects. *PLoS One* 2013;8:e76091.
- Guo J, Schupf N, Mayeux RP, Gu Y. Reproducibility of serum cytokines in an elderly population. *Immun Ageing* 2020;17:29.
- Hardikar S, Song X, Kratz M, Anderson GL, Blount PL, Reid BJ, et al. Intraindividual variability over time in plasma biomarkers of inflammation and effects of long-term storage. *Cancer Causes Control* 2014;25:969–76.
- Lee S-A, Kallianpur A, Xiang Y-B, Wen W, Cai Q, Liu D, et al. Intra-individual variation of plasma adipokine levels and utility of single measurement of these biomarkers in population-based studies. *Cancer Epidemiol Biomarkers Prev* 2007;16:2464–70.
- Koelman L, Pivovarova-Ramich O, Pfeiffer AFH, Grune T, Aleksandrova K. Cytokines for evaluation of chronic inflammatory status in ageing research: reliability and phenotypic characterisation. *Immun Ageing* 2019;16:11.
- Späth F, Wibom C, Krop EJM, Johansson A-S, Bergdahl IA, Vermeulen R, et al. Biomarker dynamics in B-cell lymphoma: a longitudinal prospective study of plasma samples up to 25 years before diagnosis. *Cancer Res* 2017;77:1408–15.
- Späth F, Wibom C, Krop EJM, Santamaria AI, Johansson A-S, Bergdahl IA, et al. Immune marker changes and risk of multiple myeloma: a nested case-control study using repeated pre-diagnostic blood samples. *Haematologica* 2019;104:2456–64.
- Jonsson P, Antti H, Späth F, Melin B, Björkblom B. Identification of pre-diagnostic metabolic patterns for glioma using subset analysis of matched repeated time points. *Cancers* 2020;12:3349.
- Hallmans G, Ågren Å, Johansson G, Johansson A, Stegmayr B, Jansson J-H, et al. Cardiovascular disease and diabetes in the Northern Sweden Health and Disease Study Cohort- evaluation of risk factors and their interactions. *Scand J Public Health Suppl* 2003;31:18–24.
- Barlow L, Westergren K, Holmberg L, Talbäck M. The completeness of the Swedish Cancer Register: a sample survey for year 1998. *Acta Oncol* 2009;48:27–33.
- Douglas B, Mächler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. *J Stat Softw* 2015;67.
- Rosner B. *Fundamentals of biostatistics*. 6th ed. Belmont, CA: Thomson-Brooks/Cole; 2006.
- Ahlquist DA. Universal cancer screening: revolutionary, rational, and realizable. *NPJ Precis Oncol* 2018;2:23.
- Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. *Cell* 2010;140:883–99.
- Sánchez-Zauco N, Torres J, Gómez A, Camorlinga-Ponce M, Muñoz-Pérez L, Herrera-Goepfert R, et al. Circulating blood levels of IL-6, IFN- $\gamma$ , and IL-10 as potential diagnostic biomarkers in gastric cancer: a controlled study. *BMC Cancer* 2017;17:384.
- Clendenen TV, Lundin E, Zeleniuch-Jacquotte A, Koenig KL, Berrino F, Lukanova A, et al. Circulating inflammation markers and risk of epithelial ovarian cancer. *Cancer Epidemiol Biomarkers Prev* 2011;20:799–810.
- Shiels MS, Pfeiffer RM, Hildesheim A, Engels EA, Kemp TJ, Park J-H, et al. Circulating inflammation markers and prospective risk for lung cancer. *J Natl Cancer Inst* 2013;105:1871–80.
- Lai Y, Wang X, Zeng T, Xing S, Dai S, Wang J, et al. Serum VEGF levels in the early diagnosis and severity assessment of non-small cell lung cancer. *J Cancer* 2018;9:1538–47.

41. Pan YW, Zhou ZG, Wang M, Dong JQ, Du KP, Li S, et al. Combination of IL-6, IL-10, and MCP-1 with traditional serum tumor markers in lung cancer diagnosis and prognosis. *Genet Mol Res* 2016;15.
42. Yang M-J, Guo J, Ye Y-F, Chen S-H, Peng L-X, Lin C-Y, et al. Decreased macrophage inflammatory protein (MIP)-1 $\alpha$  and MIP-1 $\beta$  increase the risk of developing nasopharyngeal carcinoma. *Cancer Commun* 2018;38:7.
43. Song M, Sasazuki S, Camargo MC, Shimazu T, Charvat H, Yamaji T, et al. Circulating inflammatory markers and colorectal cancer risk: a prospective case-cohort study in Japan. *Int J Cancer* 2018;143:2767–76.
44. Makgoeng SB, Bolanos RS, Jeon CY, Weiss RE, Arah OA, Breen EC, et al. Markers of immune activation and inflammation, and non-Hodgkin lymphoma: a meta-analysis of prospective studies. *JNCI Cancer Spectr* 2019;2:pkv082.
45. Platz EA, Sutcliffe S, De Marzo AM, Drake CG, Rifai N, Hsing AW, et al. Intra-individual variation in serum C-reactive protein over 4 years: an implication for epidemiologic studies. *Cancer Causes Control* 2010;21:847–51.
46. Simmons AR, Clarke CH, Badgwell DB, Lu Z, Sokoll LJ, Lu KH, et al. Validation of a biomarker panel and longitudinal biomarker performance for early detection of ovarian cancer. *Int J Gynecol Cancer* 2016;26:1070–7.
47. Pepe MS, Janes H, Longton G, Leisenring W, Newcomb P. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. *Am J Epidemiol* 2004;159:882–90.
48. Brodin P, Davis MM. Human immune system variation. *Nat Rev Immunol* 2017;17:21–9.
49. Nadler DL, Zurbenko IG. Estimating cancer latency times using a Weibull model. *Adv Epidemiol* 2014;2014.
50. Enroth S, Berggrund M, Lycke M, Broberg J, Lundberg M, Assarsson E, et al. High throughput proteomics identifies a high-accuracy 11 plasma protein biomarker signature for ovarian cancer. *Commun Biol* 2019;2:221.